Researchers used [177Lu]Lu-DOTA-hG250, targeting the overexpressed carbonic anhydrase IX (CAIX) in ccRCC, in combination with anti-PD-1 and anti-CTLA-4 ICIs. This evidence concerns the gene CA9 and nonpapillary renal cell carcinoma.